Tobira Therapeutics (TBRA) Reports Q2 Loss Per Share of $0.99

Tobira Therapeutics (NASDAQ: TBRA) reported Q2 EPS of ($0.99), versus ($19.62) reported last year. Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Tobira Therapeutics (TBRA) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Moody’s upgrades Cushman & Wakefield rating to Ba3 on debt reduction
• UBS Upgrades Nan Ya Plastics Corp. (1303:TT) to Buy